CNBP researchers (CNBP CI Nicki Packer pictured) are coauthors on an exciting new paper reporting on the design and development of upconversion immune-nanohybrids (UINBs) that have demonstrated potential for prostate cancer cell diagnostic detection.
Journal: Scientific Reports.
Title: Stable Upconversion Nanohybrid Particles for Specific Prostate Cancer Cell Immunodetection.
Authors: Yu Shi, Bingyang Shi, Arun V Everest Dass, Yiqing Lu, Nima Sayyadi, Liisa Kautto, Robert D Willows, Roger Chung, James Piper, Helena Nevalainen, Bradley Walsh, Dayong Jin and Nicolle H Packer.
Abstract: Prostate cancer is one of the male killing diseases and early detection of prostate cancer is the key for better treatment and lower cost. However, the number of prostate cancer cells is low at the early stage, so it is very challenging to detect. In this study, we successfully designed and developed upconversion immune-nanohybrids (UINBs) with sustainable stability in a physiological environment, stable optical properties and highly specific targeting capability for early-stage prostate cancer cell detection. The developed UINBs were characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), dynamic light scattering (DLS) and luminescence spectroscopy. The targeting function of the biotinylated antibody nanohybrids were confirmed by immunofluorescence assay and western blot analysis. The UINB system is able to specifically detect prostate cancer cells with stable and background-free luminescent signals for highly sensitive prostate cancer cell detection. This work demonstrates a versatile strategy to develop UCNPs based sustainably stable UINBs for sensitive diseased cell detection.
The paper is accessible online.